Table of Content

08 March 2022, Volume 49 Issue 3 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Original Articles

Effects of PSIP1 gene silencing on migration and invasion of oral squamous cell carcinoma cells Shi Yu, Chen Xi, Xu Mengqi, Zhang Yingying, Ji Honghai, Jiang Yingying 2022, 49 (3):  129-133.  doi: 10.3760/cma.j.cn371439-20210917-00022 Abstract ( 386 )   HTML ( 70 )   PDF (11321KB) ( 161 )   Save Objective To investigate the expression of PC4 and SFRS1 interacting protein 1 (PSIP1) in oral squamous cell carcinoma cells and the effects of PSIP1 silencing on the migration and invasion of oral squamous cell carcinoma cells, and to preliminarily explore its mechanism. Methods The PSIP1 gene of oral squamous cell carcinoma cell line HN30 was silenced by RNA interference technique. HN30 cells were divided into si-NC group (transfected with siRNA-NC) and si-PSIP1 group (transfected with siRNA-PSIP1). Quantitative real-time PCR was used to detect the expression of PSIP1 mRNA. Scratch test and Transwell invasion test were used to detect the migration and invasion abilities of HN30 cells, and Western blotting was used to detect the expression levels of epithelial-mesenchymal transformation (EMT) related proteins in HN30 cells of the two groups. Results The relative expression levels of PSIP1 of HN30 cells in the si-NC group and si-PSIP1 group were 1.00±0.00 and 0.21±0.06 respectively, with a statistically significant difference (t=22.30, P=0.002). The scratch healing rates of the si-NC group and si-PSIP1 were (48.21±4.66)% and (42.05±11.74)% at 12 h respectively, with no statistically significant difference (t=1.46, P=0.173), and the scratch healing rates of the two groups were (86.61±6.06)% and (67.76±3.62)% at 24 h respectively, with a statistically significant difference (t=8.01, P<0.001). The invasion numbers of HN30 cells in the si-NC group and si-PSIP1 group were 91.00±7.05 and 23.34±4.98, and there was a statistically significantly difference (t=19.20, P<0.001). Compared with the si-NC group, the migration and invasion abilities of HN30 cells in the si-PSIP1 group decreased significantly (all P<0.001). The expression levels of E-cadherin of the si-NC group and si-PSIP1 group were 1.06±0.02 and 1.43±0.13 respectively, with a statistically significant difference (t=-4.94, P=0.036), and the expression levels of N-cadherin were 1.00±0.04 and 0.57±0.14 respectively, with a statistically significant difference (t=5.03, P=0.007). Compared with the si-NC group, the expression level of E-cadherin in the si-PSIP1 group increased, while the expression level of N-cadherin decreased. Conclusion Silencing the expression of PSIP1 can significantly inhibit the migration and invasion of HN30 cells, and the mechanism may be related to the effect of PSIP1 on the EMT pathway of oral squamous cell carcinoma. Figures and Tables | References | Related Articles | Metrics

Efficacy analysis of anlotinib combined with chemotherapy for advanced non-small cell lung cancer after failure of second-line chemotherapy Sheng Xiao'an, Wang Chao, Xiao Xin, Tong Sihao 2022, 49 (3):  134-139.  doi: 10.3760/cma.j.cn371439-20210115-00023 Abstract ( 332 )   HTML ( 56 )   PDF (4122KB) ( 207 )   Save Objectiv e To observe the efficacy and safety of anlotinib combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who failed second-line chemotherapy. Methods A retrospective analysis was performed on 80 patients with advanced NSCLC who had failed second-line chemotherapy admitted in the Department of Oncology of Chaohu Hospital of Anhui Medical University from January 2017 to October 2019, and the patients were divided into control group (n=36) and observation group (n=44) according to the different treatment regimens. The control group was given pemetrexed + cisplatin, and the observation group adopted pemetrexed + cisplatin + anlotinib. The objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), overall survival (OS), changes in levels of serum vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) and treatment-related adverse reactions were compared between the two groups. Results After 2 cycles of treatment, the ORR in the control group and observation group were 5.56% (2/36) and 18.18% (8/44), with no statistically significant difference (χ2=1.85, P=0.174). The DCR in the two groups were 58.33% (21/36) and 81.82% (36/44), and the DCR in the observation group was significantly higher than that in the control group, with a statistically significant difference (χ 2=5.33, P=0.021). The median PFS in the two groups were 4.0 months and 6.0 months, and the median PFS in the observation group was longer than that in the control group, with a statistically significant difference (χ 2=28.47, P<0.001). The median OS in the two groups were 13.0 months and 14.8 months, with no statistically significant difference (χ2=1.56, P=0.212). The levels of serum VEGF [(21.72±5.42) ng/L vs. (36.97±7.53) ng/L, t=14.13, P<0.001; (16.61±4.14) ng/L vs. (38.85±8.61) ng/L, t=23.09, P<0.001], CEA [(4.91±1.58) ng/ml vs. (6.62±2.84) ng/ml, t=4.64, P<0.001; (3.07±1.32) ng/ml vs. (7.08±3.31) ng/ml, t=11.50, P<0.001] and CA199 [(16.83±5.23) U/ml vs. (20.95±7.94) U/ml, t=3.75, P<0.001; (13.37±5.85) U/ml vs. (21.66±8.72) U/ml, t=7.55, P<0.001] in the control group and observation group after 2 cycles of treatment were significantly decreased compared with those before treatment, and the levels of serum VEGF, CEA and CA199 in the observation group were significantly lower than those in the control group (t=4.78, P<0.001; t=5.68, P<0.001; t=2.76, P=0.007). The incidence of elevated blood pressure in the observation group was significantly higher than that in the control group [25.00% (11/44) vs. 2.78% (1/36), χ 2=7.67, P=0.006]. Conclusion Pemetrexed + cisplatin + anlotinib regimen for patients with advanced NSCLC who failed second-line chemotherapy can improve DCR, prolong PFS and improve the levels of serum tumor-related markers, with controllable adverse reactions. Figures and Tables | References | Related Articles | Metrics

Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu 2022, 49 (3):  140-145.  doi: 10.3760/cma.j.cn371439-20210813-00024 Abstract ( 271 )   HTML ( 35 )   PDF (4342KB) ( 125 )   Save aObjective To explore the clinical efficacy of different doses of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and the adverse reactions. Methods A total of 69 patients with NSCLC diagnosed in the No. 901 Hospital of the Chinese People's Liberation Army Joint Logistics Support Force were selected from January 2018 to June 2020, and were divided into chemotherapy alone group (docetaxel+cisplatin was used), apatinib group A [apatinib (0.25 g)+docetaxel+cisplatin was used] and apatinib group B [apatinib (0.50 g)+docetaxel+cisplatin was used] according to random number table method, with 23 cases in each group. The objective response rate (ORR), disease control rate (DCR), median overall survival (OS), median progression-free survival (PFS), and incidences of adverse reactions were compared between the three groups of patients. Results One patients in the apatinib group B withdrew from the study due to acute myocardial infarction. After 4 cycless of treatment, the ORR of the patients in the chemotherapy alone group, apatinib group A and apatinib group B were 17.39% (4/23), 47.83% (11/23) and 54.55% (12/22) respectively, with a statistically significant difference (χ2=7.41, P=0.024). The ORR of the apatinib group B was higher than that of the chemotherapy alone group, with a statistically significant difference (χ 2=6.77, P=0.009). There were no statistically significant differences in ORR between the apatinib group A and chemotherapy alone group, the apatinib group A and apatinib group B (χ 2=4.85, P=0.028; χ 2=0.20, P=0.652). The DCR of the patients in the three groups were 47.83% (11/23), 78.26% (18/23) and 86.36% (19/22) respectively, with a statistically significant difference (χ 2=9.03, P=0.011). The DCR of the apatinib group B was higher than that of the chemotherapy alone group, with a statistically significant difference (χ2=7.52, P=0.006). There were no statistically significant differences in DCR between the apatinib group A and the chemotherapy alone group, the apatinib group A and apatinib group B (χ 2=4.57, P=0.033; χ 2=0.51, P=0.477). The median OS of the patients in the three groups were 6.8, 9.2 and 9.9 months respectively, with a statistically significant different (χ 2=8.91, P=0.022). Compared with the chemotherapy alone group, the median OS of the apatinib group A and apatinib group B were significantly prolonged, with statistically significant differences (χ 2=7.25, P=0.036; χ 2=8.60, P=0.029). Compared with the apatinib group A, the median OS of the apatinib group B was prolonged, but there was no statistically significant different (χ 2=1.54, P=0.201). The median PFS of the patients in the three groups were 5.2, 7.7 and 8.2 months respectively, with a statistically significant different (χ 2=8.79, P=0.026). Compared with the chemotherapy alone group, the median PFS of the apatinib group A and apatinib group B were significantly prolonged, with statistically significant differences (χ 2=7.01, P=0.039; χ 2=8.36, P=0.031). Compared with the apatinib A group, the median PFS of the apatinib group B was prolonged, but there was no statistically significant different (χ 2=1.68, P=0.186). There were statistically significant differences in the incidences of fatigue [34.78% (8/23) vs. 65.22% (15/23) vs. 72.73% (16/22), χ 2=7.50, P=0.024], hypertension [4.35% (1/23) vs. 34.78% (8/23) vs. 68.18% (15/22), χ 2=20.07, P<0.001], hand-foot syndrome [4.35% (1/23) vs. 43.48% (10/23) vs. 72.73% (16/22), χ 2=22.28, P<0.001] and oral mucositis [8.70% (2/23) vs. 39.13% (9/23) vs. 72.73% (16/22), χ 2=19.26, P<0.001] among the three groups. Compared with the chemotherapy alone group, the incidences of hypertension and hand-foot syndrome in the apatinib group A and the incidences of fatigue, hypertension, hand-foot syndrome and oral mucositis in the apatinib group B were increased, with statistically significant differences (χ 2=6.77, P=0.009; χ 2=9.68, P=0.002; χ 2=6.51, P=0.011; χ 2=20.00, P<0.001; χ 2=22.37, P<0.001; χ 2=19.21, P<0.001). Conclusion Apatinib (0.50 g) combined with chemotherapy has better short-term efficacy than chemotherapy alone in advanced NSCLC. Apatinib (0.25 g) and apatinib (0.50 g) can prolong the survival of patients, but increasing the treatment dose can not achieve longer survival benefit. Figures and Tables | References | Related Articles | Metrics

Efficacy analysis of Xiyanping injection on prevention of radioactive esophagitis Liu Jia, Ge Xiaolin, Di Xiaoke, Shi Yujing, Zeng Yuting 2022, 49 (3):  146-150.  doi: 10.3760/cma.j.cn371439-20210210-00025 Abstract ( 401 )   HTML ( 26 )   PDF (3468KB) ( 194 )   Save Objective To investigate the preventive effect of Xiyanping injection on radioactive esophagitis in patients with radical radiotherapy and chemotherapy for esophageal cancer. Methods A total of 70 patients with esophageal cancer undergoing radical radiotherapy and chemotherapy were selected from the Department of Radiation Oncology of Jiangsu Provincial People's Hospital from January to September 2020. They were divided into experimental group (n=35) and control group (n=35) according to random number table method. The control group received standard concurrent radiotherapy and chemotherapy, and the experimental group received concurrent radiotherapy and chemotherapy combined with Xiyanping. The white blood cell count, neutrophil count, procalcitonin (PCT) and interleukin-6 (IL-6) levels before and after treatment were compared between the two groups, as well as the occurrences of radioactive esophagitis and radioactive pneumonia during radiotherapy. Results Before treatment, there were no significant differences in white blood cell count [4.57 (2.52)×109/L vs. 5.59 (2.23)×10 9/L] and neutrophil count [2.95 (1.66)×109/L vs. 3.69 (1.56)×10 9/L] between the control group and experimental group (Z=1.44, P=0.151; Z=1.52, P=0.130). After treatment, there were no statistically significant differences in white blood cell count [4.28 (2.50)×109/L vs. 4.25 (1.88)×10 9/L] and neutrophil count [2.99 (2.50)×109/L vs. 2.94 (1.61)×10 9/L] between the two groups (Z=0.67, P=0.503; Z=0.69, P=0.489). There were no statistically significant differences in white blood cell count and neutrophil count between the patients after treatment and before treatment in the two groups (Z=0.77, P=0.443; Z=1.08, P=0.279; Z =1.06, P=0.289; Z=0.68, P=0.495). Before treatment, there were no statistically significant differences in serum inflammation indexes PCT [0.02 (0.03) μg/L vs. 0.02 (0.05) μg/L] and IL-6 [0.04 (0.21) μg/L vs. 0.04 (0.12) μg/L] between the two groups (Z=0.70, P=0.482; Z=0.77, P=0.439). After treatment, there were statistically significant differences in serum inflammation indexes PCT [0.06 (0.17) μg/L vs. 0.03 (0.08) μg/L] and IL-6 [0.10 (0.25) μg/L vs. 0.01 (0.08) μg/L] between the two groups (Z=2.08, P=0.038; Z=2.92, P=0.003). There were no statistically significant differences in serum inflammation indexes PCT and IL-6 in the experimental groups after treatment compared with before treatment (Z=1.20, P=0.230; Z=1.19, P=0.235). In the control group, the serum inflammation index PCT level increased after treatment compared with before treatment, with a statistically significant difference (Z=2.82, P=0.005), and the serum inflammation index IL-6 level increased compared with before treatment, but with no statistically significant difference (Z=1.41, P=0.158). During the treatment, the incidence of radioactive esophagitis in the two groups was mainly grade Ⅰ-Ⅱ, with 24 cases in the control group and 28 cases in the experimental group. There were 8 patients with grade Ⅲ-Ⅳ radioactive esophagitis in the control group and 1 in the experimental group. There was a statistically significant difference in the occurrence of radioactive esophagitis between the two groups (χ2=10.34, P=0.035). During the treatment period, most patients with radioactive pneumonia were rated as grade 0. There were 10 cases of mild radioactive pneumonia (grade Ⅰ-Ⅱ) in the control group had and 6 cases in the experimental group. There were 2 cases of grade Ⅲ radioactive pneumonia in the control group and experimental group respectively. There was no grade Ⅳ radioactive pneumonia in either group. There was no significant difference in radioactive pneumonia between the two groups (χ 2=1.34, P=0.720). Conclusion Xiyanping injection can prevent the rise of serum inflammatory index PCT and reduce the severity of radioactive esophagitis in patients with esophageal cancer after treatment. Figures and Tables | References | Related Articles | Metrics

Comparison of 2018 and 2009 FIGO staging system of cervical cancer and analysis of prognostic factors Yuan Chenyang, Zhou Juying, Du Xiao, Ji Huan, Zhao Tianyi 2022, 49 (3):  151-163.  doi: 10.3760/cma.j.cn371439-20211015-00026 Abstract ( 581 )   HTML ( 47 )   PDF (9328KB) ( 150 )   Save Objective To compare the differences in distribution and prognosis of cervical cancer patients in the 2009 and 2018 editions of International Federation of Gynecology and Obstetrics (FIGO) staging, and to analyze the prognostic factors of cervical cancer patients. Methods The clinical data of 524 cervical cancer patients admitted to the First Affiliated Hospital of Soochow University from January 2010 to December 2018 were retrospectively analyzed. The cases were staged according to the 2009 and 2018 FIGO staging, and the Kendall τb coefficient was calculated to compare the consistency of the distribution of the two stages. Kaplan-Meier was used for survival analysis, and log-rank test was used to test the difference of prognosis in each stage. Cox-regression was used to analyze the prognostic factors of cervical cancer patients. Results In the 2009 FIGO edition of staging, 1 case of stage ⅠB1 was reduced to stage ⅠA1 due to the microscopic infiltration depth <5 mm, 51 cases of stage ⅠB1 were raised to stage ⅠB2 due to 2 cm<the maximum diameter of the tumor≤4 cm, and 43 cases of stage ⅠB2 were raised to stage ⅠB3 due to the maximum diameter of the tumor>4 cm. A total of 119 cases raised to stage ⅢC1 due to pelvic lymph node metastasis, and 11 cases raised to stage ⅢC2 due to para-aortic lymph node metastasis. The distribution of cases in the two stages was consistent (τb=0.61, P<0.001). There were statistically significant differences in overall survival (OS) (χ 2=107.13, P<0.001; χ 2=93.02, P<0.001; χ 2=92.74, P<0.001) and progression-free survival (PFS) (χ 2=91.95, P<0.001; χ 2=77.69, P<0.001; χ 2=73.27, P<0.001) among patients with different stages of FIGO in 2018 (ⅠA, ⅠB, Ⅱ, ⅢA, ⅢB, ⅢC1, ⅢC2, Ⅳ) and 2009 (ⅠA, ⅠB, Ⅱ, ⅢA, ⅢB, Ⅳ) and patients with different T stages (T1, T2, T3, T4). There were statistically significant differences in OS (χ 2=20.71, P<0.001) and PFS (χ 2=24.25, P<0.001) in 2018 FIGOⅠB and ⅢC stages, and there was a statistically significant difference in OS between stage ⅢC1 and stage ⅠB2 (χ 2=6.18, P=0.013). Multivariate analysis showed that age (HR=1.88, 95%CI: 1.08-3.28, P=0.026), pathological type (HR=2.11, 95%CI: 1.04-4.27, P=0.038), lymph node metastasis (HR=2.18, 95%CI: 1.34-3.56, P=0.002), parametrial spread (HR=2.56, 95%CI: 1.52-4.29, P<0.001), maximum tumor diameter (HR=1.98, 95%CI: 1.18-3.30, P=0.009), squamous cell carcinoma antigen (SCCA) positive after treatment (HR=4.49, 95%CI: 2.09-9.68, P<0.001) and Hemoglobin (HB) level before treatment (HR=0.58, 95%CI: 0.35-0.96, P=0.035) were independent risk factors for OS in patients with cervical cancer. According to the 2018 FIGO stage, the 5-year OS rates of patients with stage ⅠB1, ⅠB2, ⅠB3 were 100%, 97.1% and 87.9% respectively, with a statistically significant difference (χ 2=7.79, P=0.020), and there was a statistically significant difference between stage ⅠB1 and ⅠB3 (χ 2=5.55, P=0.019). According to the 2009 FIGO stage, the 5-year OS rates of patients with stage ⅠB1 and ⅠB2 were 95.7% and 84.3% respectively, with a statistically significant difference (χ 2=9.08, P=0.003). For patients with 2018 FIGO stage ⅠB, SCCA positive after treatment (HR=1 172.50, 95%CI: 10.37-132 554.51, P=0.003) was an independent risk factor for OS, and differentiation degree (HR=0.09, 95%CI: 0.01-0.81, P=0.032), treatment method (HR=0.17, 95%CI: 0.04-0.71, P=0.015) and SCCA positive after treatment (HR=190.68, 95%CI: 14.27-2 547.67, P<0.001) were independent risk factors for PFS. For patients with 2018 FIGO stage ⅠB, stage (HR=9.56, 95%CI: 2.38-38.32, P=0.001), SCCA positive after treatment (HR=126.32, 95%CI: 12.36-1 290.60, P<0.001) and lymph node metastasis (HR=20.07, 95%CI: 3.63-111.11, P=0.001) were independent risk factors for OS, and differentiation degree (HR=0.11, 95%CI: 0.02-0.63, P=0.013), treatment method (HR=0.22, 95%CI: 0.06-0.75, P=0.015) and SCCA positive after treatment (HR=43.83, 95%CI: 7.94-241.84, P<0.001) were independent risk factors for PFS. According to the 2018 FIGO stage, the 5-year OS rates of patients with stage ⅡA and ⅡB were 95.7% and 75.6% respectively, with a statistically significant difference (χ 2=13.96, P<0.001). The 5-year PFS rates of patients with stage ⅡA and ⅡB were 83.1% and 67.1% respectively, with a statistically significant difference (χ 2=7.61, P=0.006). According to the 2009 FIGO stage, the 5-year OS rates of patients with stage ⅡA and ⅡB were 90.9% and 75.0% respectively, with a statistically significant difference (χ 2=8.85, P=0.003). The 5-year PFS rates of patients with stage ⅡA and ⅡB were 75.7% and 66.7% respectively, with a statistically significant difference (χ 2=4.07, P=0.044). For patients with 2018 FIGO stage Ⅱ, pathological type (HR=20.28, 95%CI: 2.93-140.32, P=0.002) and stage (HR=4.35, 95%CI: 1.02-18.55, P=0.047) were independent risks factors for OS. For patients with 2009 FIGO stage Ⅱ, pathological type (HR=5.82, 95%CI: 1.62-20.94, P=0.007) was an independent risk factor for OS, and pathological type (HR=3.09, 95%CI: 1.22-7.85, P=0.017) and lymph node metastasis (HR=2.07, 95%CI: 1.22-3.51, P=0.007) were independent risk factors for PFS. For patients with 2018 FIGO stage Ⅲ, maximum tumor diameter (HR=3.31, 95%CI: 1.45-7.56, P=0.005) and SCCA positive after treatment (HR=4.67, 95%CI: 1.22-17.86, P=0.024) were independent risk factors for OS, and pathological type (HR=4.15, 95%CI: 1.47-11.77, P=0.007) and SCCA positive after treatment (HR=3.96, 95%CI: 1.45-10.86, P=0.007) were independent risk factors for PFS. Conclusion The 2018 and 2009 FIGO staging have a good distribution consistency in the cervical cancer patients, and the 2018 FIGO stage ⅠB has more advantages in judging the prognosis, but stage ⅢC cannot accurately judge the prognosis. Lymph node metastasis and maximum tumor diameter are more important prognostic factors. Figures and Tables | References | Related Articles | Metrics

Reviews

NUF2 and tumor prognosis Ren Meng, Yang Lu, Zhao Xiaoting, Yue Wentao 2022, 49 (3):  164-167.  doi: 10.3760/cma.j.cn371439-20211025-00027 Abstract ( 353 )   HTML ( 33 )   PDF (2630KB) ( 195 )   Save NUF2 is responsible for the attachment of kinetochore-microtubules and proper chromosome segregation during mitosis. NUF2 is highly expressed in hepatocellular carcinoma, pancreatic cancer, esophageal cancer, non-small cell lung cancer, breast cancer and other tumor tissues and cells, and can be used as prognostic markers. Further clarifying the relationship between NUF2 and tumor prognosis can provide help for the application of NUF2 in prognostic assessment of cancers. References | Related Articles | Metrics

Application of artificial intelligence in the target delineation of radiotherapy Yan Danfang, Wang Lihong, Ye Hongxing, Yan Senxiang 2022, 49 (3):  168-172.  doi: 10.3760/cma.j.cn371439-20220104-00028 Abstract ( 567 )   HTML ( 35 )   PDF (3982KB) ( 292 )   Save Artificial intelligence is the use of computer algorithms to copy or simulate human behavior, giving machines human-like ability. With the rapid development of radiotherapy technology, artificial intelligence has great potential value in all stages of radiotherapy. Image segmentation is the premise of target delineation using artificial intelligence. The commonly used methods in clinic mainly include automatic segmentation based on deep learning and atlas library. The technology of artificial intelligence in organs at risk delineation is relatively mature, which can significantly shorten the delineation time and improve the efficiency. The delineation of tumor targets has achieved some success, the accuracy still needs to be further improved. Artificial intelligence technology makes the target delineation more and more efficient, and the consistency and repeatability have been significantly improved. It is expected to provide more accurate and individualized treatment for patients. References | Related Articles | Metrics

Mechanism of drug induced ferroptosis in the treatment of head and neck tumors Zeng Yan, Luo Pan, Wang Ziqi, Wu Weili 2022, 49 (3):  173-176.  doi: 10.3760/cma.j.cn371439-20210922-00029 Abstract ( 216 )   HTML ( 24 )   PDF (2960KB) ( 344 )   Save Ferroptosis is drived by lipid reactive oxygen species, which plays an important role in the development of tumors. It has been found that a variety of clinical medicines, such as artemisinin derivatives, itraconazole, sulfasala zine, cucurbitacin B, paclitaxel, disulfiram/copper can induce ferroptosis and inhibit tumor growth in head and neck cancer (HNC) through different mechanisms. To study the regulatory mechanism of ferroptosis induced by commonly used drugs in the treatment of HNC can provide reference for the targeted treatment of ferroptosis in HNC. References | Related Articles | Metrics

Predictive value of serum inflammatory markers in immunotherapy of non-small cell lung cancer Luo Hong, Yin Hong, Hu Guangyue, Tao Hong 2022, 49 (3):  177-180.  doi: 10.3760/cma.j.cn371439-20211115-00030 Abstract ( 227 )   HTML ( 35 )   PDF (3005KB) ( 214 )   Save Immune checkpoint inhibitors (ICIs) can not only prolong the survival time of patients with non-small cell lung cancer (NSCLC) in a short time, but also achieve a lasting response to the tumor. However, there has been significant heterogeneity in the efficacy of ICIs among patients with different types of NSCLC, and there has been still a lack of universal biomarkers to predict the benefit of ICIs treatment. Inflammation has played a definite role in the occurrence and development of tumors, and a variety of inflammatory markers in serum also have become clinical indicators reflecting immune status, such as lactate dehydrogenase, C-reactive protein, serum neutrophils, lymphocytes, platelets and other indicators. These inflammatory markers are easy to obtain and are associated with the prognosis of a variety of solid tumors. References | Related Articles | Metrics

Progression of radiotherapy for brain metastases in non-small cell lung cancer Ji Huan, Zhou Juying, Ma Chenying, Xu Xiaoting, Qin Songbing 2022, 49 (3):  181-184.  doi: 10.3760/cma.j.cn371439-20220104-00031 Abstract ( 276 )   HTML ( 41 )   PDF (3008KB) ( 267 )   Save Brain metastases are one of the most common distant metastases in patients with non-small cell lung cancer (NSCLC), and the prognosis will be extremely poor. The effect of chemotherapy and operation is limited. As a standard treatment, radiotherapy is widely used in clinical practice. Radiotherapy alone includes whole brain radiotherapy, stereotactic radiotherapy and whole brain radiotherapy combined with stereotactic radiotherapy. With the continuous development of radiotherapy and the progress of gene sequencing, radiotherapy has been combined with targeted drugs, anti-angiogenic drugs and immunodrugs in the treatment of NSCLC brain metastasis, which can improve the survival of patients with NSCLC brain metastasis. References | Related Articles | Metrics

Mechanism of lncRNA and circRNA regulating the sensitivity of radiotherapy and chemotherapy in esophageal squamous cell carcinoma Zhang Junpeng, Yu Yanyan, Li Baosheng 2022, 49 (3):  185-189.  doi: 10.3760/cma.j.cn371439-20220104-00032 Abstract ( 237 )   HTML ( 31 )   PDF (3732KB) ( 285 )   Save Long non-coding RNA (lncRNA) and circular RNA (circRNA) are two important types of non-coding RNA that can regulate gene expression by directly interacting with DNA, RNA or protein. A large number of studies have shown that lncRNA and circRNA can not only predict the prognosis of patients with esophageal squamous cell carcinoma (ESCC) after radiotherapy and chemotherapy, but also affect the sensitivity of ESCC to radiotherapy and chemotherapy through competing endogenous RNA mechanisms, regulating PI3K/Akt/mTOR and Wnt/β-catenin signaling pathways, participating in DNA and protein modification, regulating the cell cycle and other pathways. In-depth research on the mechanism of lncRNA and circRNA regulating the sensitivity of ESCC to radiotherapy and chemotherapy will improve the effect of radiotherapy and chemotherapy in ESCC patients. References | Related Articles | Metrics